Karen Kaucic, M.D., is president of Evidera. In this role, she provides strategic direction and operational oversight for the company, a PPD business unit recognized as a global leader in peri- and post-approval studies, real-world evidence, health economics, outcomes research, market access, epidemiology and data analytics. In addition, she leads PPD’s rare disease and pediatric center of excellence, which develops and implements next-generation strategies to optimize clinical trial delivery in low-prevalence indications.
Dr. Kaucic joined PPD in 2009, initially leading PPD® Consulting, PPD’s product development consulting group. Immediately before assuming leadership of Evidera, Dr. Kaucic led PPD’s early development business unit, which includes two clinical pharmacology units and PPD’s early development CRO services. Prior to joining PPD, Dr. Kaucic served as senior director in oncology clinical development at MedImmune AstraZeneca. There, she led product development teams for several biologics compounds, including monoclonal antibodies, biospecific antibodies and antibody conjugates.
Earlier in her career, Dr. Kaucic was a staff pediatric oncologist and senior investigator at Children’s National Medical Center in Washington, D.C., where she established the institution’s first hematopoietic stem cell transplantation laboratory, served as an attending physician in oncology and conducted NIH-funded research in signal transduction in human neuroectodermal tumors.
Dr. Kaucic earned her medical degree from The Ohio State University followed by a pediatric residency at the same institution. She completed fellowships in pediatric hematology/oncology and transfusion medicine at Children’s National Medical Center and The Cleveland Clinic, respectively.